filmov
tv
Laurence Albigès, MD, PhD, offers opinion on whether CheckMate 214 is practice-changing
Показать описание
Dr. Albigès, Head, Genitourinary Unit, Gustave Roussy Institute, offers opinion on whether the results of CheckMate 214 are practice-changing and how combination nivolumab and ipilimumab fits in among other immuno-oncology (I-O) regimens for the 1st line treatment of advanced renal cell carcinoma (RCC)
0:00:59
0:00:45
0:01:54
0:01:08
0:08:57
0:00:52
0:01:32
0:03:01
0:00:50
0:01:34
0:01:05
0:01:12
0:01:03
0:01:32
0:04:21
0:04:48
0:01:56
0:06:15
0:04:44
0:02:28
0:12:07
0:01:52
0:03:59
0:01:11